title: Cholinergic signaling in the hippocampus regulates social stress resilience and anxiety- and depression-like behavior.
abstract: Symptoms of depression can be induced in humans through blockade of acetylcholinesterase (AChE) whereas antidepressant-like effects can be produced in animal models and some clinical trials by limiting activity of acetylcholine (ACh) receptors. Thus, ACh signaling could contribute to the etiology of mood regulation. To test this hypothesis, we administered the AChE inhibitor physostigmine to mice and demonstrated an increase in anxiety- and depression-like behaviors that was reversed by administration of nicotinic or muscarinic antagonists. The behavioral effects of physostigmine were also reversed by administration of the selective serotonin reuptake inhibitor fluoxetine. Administration of fluoxetine also increased AChE activity throughout the brain, with the greatest change in the hippocampus. To determine whether cholinergic signaling in the hippocampus could contribute to the systemic effects of cholinergic drugs, we infused physostigmine or virally delivered shRNAs targeting AChE into the hippocampus. Both pharmacological and molecular genetic decreases in hippocampal AChE activity increased anxiety- and depression-like behaviors and decreased resilience to repeated stress in a social defeat paradigm. The behavioral changes due to shRNA-mediated knockdown of AChE were rescued by coinfusion of an shRNA-resistant AChE transgene into the hippocampus and reversed by systemic administration of fluoxetine. These data demonstrate that ACh signaling in the hippocampus promotes behaviors related to anxiety and depression. The sensitivity of these effects to fluoxetine suggests that shRNA-mediated knockdown of hippocampal AChE represents a model for anxiety- and depression-like phenotypes. Furthermore, abnormalities in the cholinergic system may be critical for the etiology of mood disorders and could represent an endophenotype of depression.
authors: Department of Psychiatry, Yale University School of Medicine, New Haven, CT 06508, USA.
authors: Yann S
authors: YS
authors: Mineur
authors: Adetokunbo
authors: A
authors: Obayemi
authors: Mattis B
authors: MB
authors: Wigestrand
authors: Gianna M
authors: GM
authors: Fote
authors: Cali A
authors: CA
authors: Calarco
authors: Alice M
authors: AM
authors: Li
authors: Marina R
authors: MR
authors: Picciotto
mesh_terms: D000110:Acetylcholinesterase / Q000378:metabolism; D000818:Animals; D000928:Antidepressive Agents / Q000494:pharmacology / Q000627:therapeutic use; D001007:Anxiety / Q000150:complications / Q000188:drug therapy / Q000378:metabolism / Q000523:psychology*; D001522:Behavior, Animal / Q000187:drug effects; D018680:Cholinergic Antagonists / Q000494:pharmacology / Q000627:therapeutic use; D059329:Cholinergic Neurons / Q000187:drug effects / Q000378:metabolism* / Q000473:pathology; D000229:Dependovirus / Q000378:metabolism; D003863:Depression / Q000150:complications / Q000188:drug therapy / Q000378:metabolism / Q000523:psychology*; D005473:Fluoxetine / Q000494:pharmacology / Q000627:therapeutic use; D055785:Gene Knockdown Techniques; D019417:Hindlimb Suspension; D006624:Hippocampus / Q000187:drug effects / Q000378:metabolism* / Q000473:pathology; D006801:Humans; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D010641:Phenotype; D010830:Physostigmine; D034741:RNA, Small Interfering / Q000378:metabolism; D011950:Receptors, Cholinergic / Q000378:metabolism; D055500:Resilience, Psychological; D015398:Signal Transduction / Q000187:drug effects; D013315:Stress, Psychological / Q000150:complications / Q000188:drug therapy / Q000378:metabolism*; D013997:Time Factors
chemical_list: D000928:Antidepressive Agents; D018680:Cholinergic Antagonists; D034741:RNA, Small Interfering; D011950:Receptors, Cholinergic; D005473:Fluoxetine; D010830:Physostigmine; D000110:Acetylcholinesterase
references: Biol Psychiatry. 2012 Jan 1;71(1):75-83
references: 21978521
references: Chem Biol Interact. 2010 Sep 6;187(1-3):72-7
references: 20153304
references: J Histochem Cytochem. 1964 Mar;12:219-21
references: 14187330
references: J Neurosci. 2011 Jun 22;31(25):9084-92
references: 21697359
references: J Physiol. 2005 Jan 1;562(Pt 1):81-8
references: 15528238
references: J Clin Psychopharmacol. 2008 Jun;28(3):340-4
references: 18480694
references: Biol Psychiatry. 1991 Jan 15;29(2):127-38
references: 1847308
references: Science. 2003 Jul 18;301(5631):386-9
references: 12869766
references: Behav Pharmacol. 2011 Aug;22(4):291-9
references: 21566524
references: Nat Neurosci. 2010 Jun;13(6):745-52
references: 20473292
references: Pharmacol Biochem Behav. 2000 May;66(1):65-72
references: 10837844
references: Trends Pharmacol Sci. 2010 Dec;31(12):580-6
references: 20965579
references: Neuropharmacology. 2007 Apr;52(5):1256-62
references: 17320916
references: J Mol Med (Berl). 2000;78(4):228-36
references: 10933585
references: Chem Biol Interact. 1999 May 14;119-120:349-60
references: 10421471
references: Arch Gen Psychiatry. 2006 Oct;63(10):1121-9
references: 17015814
references: Neuron. 2012 Oct 4;76(1):116-29
references: 23040810
references: Ann N Y Acad Sci. 1995 May 10;757:169-79
references: 7611672
references: Brain Res Bull. 1998;45(1):89-93
references: 9434207
references: Behav Neurosci. 1998 Apr;112(2):352-9
references: 9588482
references: Science. 2006 Feb 10;311(5762):864-8
references: 16469931
references: Psychiatry Res. 1981 Feb;4(1):89-94
references: 7012883
references: Science. 2011 Jun 10;332(6035):1330-2
references: 21659607
references: Curr Psychiatry Rep. 2011 Dec;13(6):443-5
references: 21976067
references: Psychoneuroendocrinology. 1987;12(3):167-84
references: 3615747
references: Cell. 2007 Oct 19;131(2):391-404
references: 17956738
references: Chem Biol Interact. 2005 Dec 15;157-158:71-8
references: 16243306
references: Proc Natl Acad Sci U S A. 2000 Jul 18;97(15):8647-52
references: 10890884
references: Psychopharmacology (Berl). 2003 May;167(3):251-6
references: 12669178
references: Neurosci Biobehav Rev. 2005;29(4-5):571-625
references: 15890404
references: Lancet. 1972 Sep 23;2(7778):632-5
references: 4116781
references: Neurosci Biobehav Rev. 1993 Spring;17(1):51-68
references: 8455816
references: Pharmacol Biochem Behav. 1991 Feb;38(2):315-20
references: 2057501
references: Mol Pharmacol. 2008 Dec;74(6):1641-8
references: 18776044
references: Nat Rev Neurosci. 2001 Apr;2(4):294-302
references: 11283752
references: Neuroscience. 1996 Oct;74(3):767-74
references: 8884772
references: Am J Psychiatry. 2012 Aug;169(8):851-9
references: 22772158
references: Histochemistry. 1986;84(4-6):575-9
references: 3721921
references: Nature. 1998 May 28;393(6683):373-7
references: 9620801
references: Science. 2002 Jan 18;295(5554):508-12
references: 11799248
references: J Mol Neurosci. 2010 Jan;40(1-2):47-55
references: 19711202
references: Pharmacol Biochem Behav. 1992 Jan;41(1):23-7
references: 1539073
references: Am J Psychiatry. 2010 Nov;167(11):1305-20
references: 20843874
references: Nat Rev Neurosci. 2009 May;10(5):383-90
references: 19377503
references: Proc Natl Acad Sci U S A. 2012 Jul 10;109(28):11360-5
references: 22733786